Global incidence, prevalence and disease burden of silicosis: 30 years' overview and forecasted trends.
Global burden of Disease (GBD)
Prediction
Silicosis
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
17 07 2023
17 07 2023
Historique:
received:
03
03
2023
accepted:
12
07
2023
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Globally, silicosis accounts for 90% of all pneumoconiosis cases and is a serious public health issue. It is characterized by progressive inflammation and irreversible pulmonary fibrosis. A comprehensive analysis at temporal, spatial and population levels with the most updated data from GBD 2019 is provided in this study to estimate the disease burden of silicosis from 1990 to 2019 and make predictions to 2029. We delineated silicosis data on incidence, prevalence, and disability-adjusted life years (DALYs) as well as age-standardized rates (ASRs) across 30 years from GBD 2019. Joinpoint regression analysis was employed to detect temporal changes and estimate annual percentage change (APC) of each trend segment. Measures were stratified by time, location, age, and sociodemographic index (SDI). Back propagation artificial neural network (BP-ANN) model was applied to elaborate ASR trends from 1990 to 2019 and projections to the next 10 years. Globally, silicosis incident, prevalent cases, and DALYs increased by 64.6%, 91.4%, and 20.8%, respectively. However, all the corresponding ASRs showed overall downward trends with an estimated average APC (AAPC) of -0.5(-0.7 to -0.3), -0.2(-0.5 to 0.0), and - 2.0(-2.2 to -1.8), respectively. Middle and high-middle SDI regions carried the heaviest disease burden. The highest disease burden of silicosis was mainly transferred to the older from 1990 to 2019. The trend of ASRs demonstrated a rapid decline between 2005 and 2019, followed by a continuous decline until 2029. Though disease burden of silicosis has been on a decline in general from 1990 to 2019, which shows a promising prospect but cannot be ignored. We should pay more attention to implementing preventive tactics and improving the life quality of present sufferers.
Sections du résumé
BACKGROUND
Globally, silicosis accounts for 90% of all pneumoconiosis cases and is a serious public health issue. It is characterized by progressive inflammation and irreversible pulmonary fibrosis. A comprehensive analysis at temporal, spatial and population levels with the most updated data from GBD 2019 is provided in this study to estimate the disease burden of silicosis from 1990 to 2019 and make predictions to 2029.
METHODS
We delineated silicosis data on incidence, prevalence, and disability-adjusted life years (DALYs) as well as age-standardized rates (ASRs) across 30 years from GBD 2019. Joinpoint regression analysis was employed to detect temporal changes and estimate annual percentage change (APC) of each trend segment. Measures were stratified by time, location, age, and sociodemographic index (SDI). Back propagation artificial neural network (BP-ANN) model was applied to elaborate ASR trends from 1990 to 2019 and projections to the next 10 years.
RESULTS
Globally, silicosis incident, prevalent cases, and DALYs increased by 64.6%, 91.4%, and 20.8%, respectively. However, all the corresponding ASRs showed overall downward trends with an estimated average APC (AAPC) of -0.5(-0.7 to -0.3), -0.2(-0.5 to 0.0), and - 2.0(-2.2 to -1.8), respectively. Middle and high-middle SDI regions carried the heaviest disease burden. The highest disease burden of silicosis was mainly transferred to the older from 1990 to 2019. The trend of ASRs demonstrated a rapid decline between 2005 and 2019, followed by a continuous decline until 2029.
CONCLUSION
Though disease burden of silicosis has been on a decline in general from 1990 to 2019, which shows a promising prospect but cannot be ignored. We should pay more attention to implementing preventive tactics and improving the life quality of present sufferers.
Identifiants
pubmed: 37461046
doi: 10.1186/s12889-023-16295-2
pii: 10.1186/s12889-023-16295-2
pmc: PMC10353232
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1366Informations de copyright
© 2023. The Author(s).
Références
Curr Opin Pulm Med. 2020 Mar;26(2):142-148
pubmed: 31895883
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Int J Mol Sci. 2021 Apr 17;22(8):
pubmed: 33920534
Int J Mol Sci. 2021 Jul 28;22(15):
pubmed: 34360876
Int Arch Occup Environ Health. 2023 Jan;96(1):45-56
pubmed: 35906431
Environ Int. 2021 Nov;156:106725
pubmed: 34171589
Nat Med. 2022 Oct;28(10):2019-2026
pubmed: 36216939
Int J Environ Res Public Health. 2022 Nov 27;19(23):
pubmed: 36497874
Rev Esp Salud Publica. 2021 Aug 25;95:
pubmed: 34429394
Occup Environ Med. 2020 Jun;77(6):407-414
pubmed: 32188634
Allergy. 2020 Nov;75(11):2805-2817
pubmed: 31989662
BMC Public Health. 2022 Jun 3;22(1):1114
pubmed: 35659279
BMC Med Inform Decis Mak. 2020 Jul 2;20(1):143
pubmed: 32616052
Lancet. 2020 Oct 17;396(10258):1250-1284
pubmed: 32861314
Respirology. 2019 Dec;24(12):1165-1175
pubmed: 31517432
Lancet. 2020 Oct 17;396(10258):1135-1159
pubmed: 33069324
Environ Health Perspect. 2010 Mar;118(3):421-6
pubmed: 20194070
Front Neuroinform. 2022 Aug 11;16:961588
pubmed: 36059864
Environ Int. 2018 Oct;119:174-185
pubmed: 29958118
Clin Chest Med. 2020 Dec;41(4):709-722
pubmed: 33153689
Thorax. 2020 Sep;75(9):798-800
pubmed: 32467338
BMC Public Health. 2020 Jun 1;20(1):829
pubmed: 32487111
Arch Bronconeumol (Engl Ed). 2019 Sep;55(9):459-464
pubmed: 30879876
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
Respirology. 2022 Jun;27(6):387-398
pubmed: 35302259
Respirology. 2022 Jun;27(6):437-446
pubmed: 35176815
Front Public Health. 2021 Sep 17;9:619581
pubmed: 34604147
Sci Total Environ. 2021 Nov 20;796:148819
pubmed: 34265615
BMC Med Inform Decis Mak. 2022 Nov 12;22(1):293
pubmed: 36371224
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326